Advertisement

Topics

A Study in Patients With Advanced or Metastatic Cancer

2014-08-27 03:13:59 | BioPortfolio

Summary

Study JWAA is a multicenter, nonrandomized, open-label, dose-escalation Phase 1 study of oral LY2780301 in patients with advanced solid tumors.

Description

JWAA will consist of the following treatment phases parts:

Part A - Dose escalation phase using a once-daily dosing schedule. Part B - Dose escalation phase using a twice-daily dosing schedule. Part C - Dose expansion phase using the maximum tolerated dose from either Part A or Part B.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Metastases, Neoplasm

Intervention

LY2780301

Location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559)
Barcelona
Spain

Status

Recruiting

Source

Eli Lilly and Company

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:59-0400

Clinical Trials [504 Associated Clinical Trials listed on BioPortfolio]

Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)

The aim of the study is to assess prospectively the impact of radiosurgery on the quality of life in patients with brain metastases.

Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.

Increasing magnetic field is known to give improvements in signal-to-noise-ratio (SNR) and spectral resolution. To investigate this, spectra from different subjects were examined using two...

Study of Resection Combined With Stereotactic Radiosurgery for 1 to 3 Brain Metastases

This study is to look more closely at the tumor removed during your surgery, and to follow your condition after your treatment. The purpose of this study is to determine what side effects...

Bone Metastases Database of Patients Treated Surgically for Impending or Pathologic Fracture of Long Bones

The aims of this study are to collect prospective data on the natural history of bone metastases (BMs) and skeleta related events (SREs),

Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension

30 Gy single fraction of SBRT for lung metastases will result in comparable oncologic outcomes to 18Gy in three fractions (or dosing to a BED

PubMed Articles [999 Associated PubMed Articles listed on BioPortfolio]

Extrapancreatic solid pseudopapillary neoplasm followed by multiple metastases: Case report.

Solid pseudopapillary neoplasm (SPN), also known as Gruber-Frantz tumor, is a rare form of neoplasm that almost exclusively occurs in the pancreas and in young females. While the potential of malignan...

Cutaneous Metastases of the Glioma.

Low grade glioma (LGG) is a very common primary brain neoplasm with a very good prognosis and the median survival of patients is approximately 8 years. With the development of current treatments such ...

Lung metastases from intracranial bleeding meningioma: A case report.

Meningioma is slow-growing benign neoplasm that derived from the meningothelial cells of the arachnoid mater, and it is the most common type of primary brain tumor. Although cases of extracranial meta...

Surgery for brain metastases: An analysis of outcomes and factors affecting survival.

For patients who develop brain metastases from solid tumors, age, KPS, primary tumor status and presence of extracranial metastases have been identified as prognostic factors. However, the factors tha...

Cutaneous Metastasis of Adenocarcinoma of the Ampulla of Vater.

Cutaneous metastases from an adenocarcinoma of the Ampulla of Vater are very rare, with only a few cases previously reported. We present here an additional case in a 57-year-old woman who complained o...

Medical and Biotech [MESH] Definitions

Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)

Surgery to remove one or more NEOPLASM METASTASES.

A highly malignant subset of neoplasms arising from the endometrial stroma. Tumors in this group infiltrate the stroma with a wide range of atypia cells and numerous mitoses. They are capable of widespread metastases (NEOPLASM METASTASIS).

A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)

More From BioPortfolio on "A Study in Patients With Advanced or Metastatic Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial